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Neurobiology of Disease
Critical Role of Astroglial Apolipoprotein E and Liver X
Receptor- Expression for Microglial A Phagocytosis
Dick Terwel,1 Knut R. Steffensen,2 Philip B. Verghese,3Markus P. Kummer,1 Jan-Åke Gustafsson,2David M. Holtzman,3
andMichael T. Heneka1
1Department of Neurology, University of Bonn, 53127 Bonn, Germany, 2Department of Biosciences and Nutrition, Karolinska Institutet, S-141 57
Huddinge, Sweden, and 3Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110
Liver X receptors (LXRs) regulate immune cell function and cholesterol metabolism, both factors that are critically involved in Alzhei-
mer’s disease (AD). To investigate the therapeutic potential of long-term LXR activation in amyloid- (A) peptide deposition in an AD
model, 13-month-old, amyloid plaque-bearing APP23 mice were treated with the LXR agonist TO901317. Postmortem analysis demon-
strated that TO901317 efficiently crossed the blood–brain barrier. Insoluble and soluble A levels in the treated APP23 mice were
reduced by 80% and 40%, respectively, compared with untreated animals. Amyloid precursor protein (APP) processing, however, was
hardly changedby the compound, suggesting that the observed effectswere insteadmediated byAdisposal. Despite the profound effect
on A levels, spatial learning in the Morris water maze was only slightly improved by the treatment. ABCA1 (ATP-binding cassette
transporter 1) and apolipoprotein E (ApoE) protein levels were increased and found to be primarily localized in astrocytes. Experiments
using primary microglia demonstrated that medium derived from primary astrocytes exposed to TO901317 stimulated phagocytosis of
fibrillar A. Conditioned medium from TO901317-treated ApoE/ or LXR/ astrocytes did not increase phagocytosis of A. In
APP23mice, long-term treatment with TO901317 strongly increased the association of microglia and A plaques. Short-term treatment
of APP/PS1mice with TO901317 also increased this association, whichwas dependent on the presence of LXR andwas accompanied by
increased ApoE lipidation. Together, these data suggest that astrocytic LXR activation and subsequent release of ApoE by astrocytes is
critical for the ability of microglia to remove fibrillar A in response to treatment with TO901317.
Introduction
Ample evidence suggests a role for innate immune function and
brain cholesterol metabolism in Alzheimer’s disease (AD) (Mul-
der and Terwel, 1998; Heneka and O’Banion, 2007). Both pro-
cesses happen to be under the control of liver X receptors (LXRs)
(Whitney et al., 2002; Zelcer and Tontonoz, 2006). Two types of
LXRs exist, LXR and LXR. LXR is found at high levels in
cholesterol-metabolizing tissues and its expression is acutely reg-
ulated (Whitney et al., 2001), while LXR is ubiquitously ex-
pressed (Baranowski, 2008). Both LXRs act as cholesterol sensors
and are activated by hydroxylated forms of cholesterol, leading to
induction of genes that encode for proteins directly responsible
for cholesterol export from the cell, such as apolipoprotein E
(ApoE), ATP-binding cassette transporters (ABCA1, ABCG1),
and sterol regulatory element-binding protein 1c (SREBP1c)
(Zelcer and Tontonoz, 2006). In humans ApoE is present as three
different isoforms, ApoE2, -3, and -4. The fact that ApoE4 is the
best described risk factor for sporadic AD (Roses, 2006) hints to a
link between this disease and cholesterol metabolism. The con-
trol of innate immune cell function by LXRs is not directly related
to cholesterol metabolism and involves interference of nuclear
factor B signaling (Zelcer and Tontonoz, 2006).
Because of the central role played by lipid metabolism in the
development of atherosclerosis (Beaven and Tontonoz, 2006),
agonists for LXRs are under development for therapy in this con-
dition and are currently being evaluated in respective clinical
trials. This encourages research into the application of LXR ago-
nists for other diseases in which lipid metabolism is implicated,
includingAD. The fact that LXRs affect dual processes implicated
in AD adds to the attraction to test these compounds in AD.
Several studies have addressed the effect of LXR stimulation in
cellular or rodent models of AD. It has been shown that the LXR
agonists TO901317 and GW3965 alter amyloid- (A) production
in neuronal and non-neuronal cell cultures overexpressing amyloid
precursor protein (APP) (Koldamova et al., 2003, 2005b; Kim et al.,
2007).
Short-term administration of LXR agonists TO901317 and
GW3965 to 5-month-old preplaque Tg2576 mice improved fear
conditioning (Riddell et al., 2007; Jiang et al., 2008) and long-
term treatment with TO901317 restored object recognition in
plaque-bearing APPSLxPS1mut mice (Vanmierlo et al., 2009).
Long-term treatment with GW3965 has been shown to reduce
plaque formation by 50% in aged Tg2576 mice (Jiang et al.,
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2008). Short-term treatments with TO901317 have shown small
reductions of soluble A40 and -42 (Koldamova et al., 2005b), or
A42 only, in hippocampus of Tg2576mice (Riddell et al., 2007).
While these studies elucidate the dependence of LXR agonist-
mediated effects on different treatment protocols, ages, and dis-
ease stages, the underlyingmechanism of LXR agonist protection
in aged APP transgenic mice and, in particular, an effect on the
removal of fibrillar A remain unclear. In the present study we
investigated the role of LXRs inmicroglial removal of fibrillar A
in vitro and after chronic stimulation of LXRs by TO901317 in
aged APP23 mice for 7 weeks from 13 months of age onwards.
Materials andMethods
Animal experiments. In the present study APP23 mice and littermate
wild-type mice were used. In the APP23 mouse line, human APP751
carrying the Swedish doublemutation (K670M/N671L) is overexpressed
sevenfold over the endogenous mouse APP. The mice were generated on
a C57BL/6 DBA/2 background and were back-crossed into C57BL/6.
APP23 mice were 13 months old at the beginning of the study. Deposi-
tion of A in APP23 mice starts at 6 months of age and continuously
increases (Sturchler-Pierrat et al., 1997), and at 12 months substantial
plaque deposition has been demonstrated (Kuo et al., 2001).Of relevance
to our present work, Sturchler-Pierrat et al. (1997) have described A
plaque-associated microglia already present at 12 months. Thus, at 13
months, when we initiated treatment with the LXR agonist, there was a
substantial A plaque deposition, and microglia associated with it, pres-
ent in APP23 mice. Mice were housed separately in individually venti-
lated cages 3 weeks in advance of the experiment, under standard
conditions (at 22°C, humidity 18%)with free access to food andwater on
a reverse dark/light cycle of 12 h light and 12 h darkness. APP23 and
controlmice received 50mg/kg TO901317 or vehicle daily by oral gavage
for 7 weeks. The vehicle was a 0.5% methylcellulose solution and the
compound was suspended by sonication. In week 5 of treatment, behav-
ioral habituation of the mice was assessed in the open field. In weeks 6
and 7, animals underwent spatial memory assessment using the Morris
water maze. For blood and tissue collection the animals were shortly anes-
thetizedby inhalationof isoflurane and receivedan injectionof 50l of 0.5M
EDTA through the left heart chamber. Blood was drawn from the left heart
chamber and stored at 80°C until compound determination. Subse-
quently,micewere transcardiallyperfusedwith ice-coldPBSandbrainswere
removed.Onehemisphere of the brainwas fixed in ice-cold 4%paraformal-
dehyde, PBS overnight, and used for immunohistochemistry. The other
hemisphere was separated into a hindbrain and a forebrain part. Brain parts
were snap-frozen in liquid nitrogen and subsequently stored at80°C until
further determination of insoluble and soluble A species, other APP pro-
cessing products, and compound determination.
Additionally, 13-month-old APP/PS1/LXR/ mice and APP/PS1/
LXR/ littermates on a C57BL/6 background were used. Parental
strains of these mice are described by Jankowsky et al. (2004) and Alberti
et al. (2000). The APP/PS1/LXR/ and APP/PS1/LXR/ mice were
treated with TO901317 as described above, but only for 6 d. CSF was
collected from the cisterna magna of these mice as previously described
(DeMattos et al., 2002). Brain hemispheres were obtained as described
for the APP23 mice and used for the immunohistochemical determina-
tion of the association of microglia with A.
Animal care and handling was performed according to the declaration
of Helsinki and approved by the local ethical committees.
Determination of TO901317 levels in blood and brain tissue. The con-
centrations of TO901317 were determined in EDTA-treated blood and
brain tissue (after homogenization in phosphate buffer, pH 7.2) by liquid
chromatography/tandem mass spectrometry (LC/MS/MS). These anal-
yses were performed on a TSQmass spectrometer (ThermoFisher Scien-
tific). The instrument was operated in the atmospheric pressure and
negative electrospray ionization mode with selected reaction monitor-
ing. Liquid chromatographywas performed on aMaxRP Synergi column
(50  2 mm, 2.5 m pore size; Phenomenex), with a gradient elution
(varying the percentages of water, methanol, and acetonitrile, and with
1% formic acid). Samples were prepared using protein precipitationwith
acetonitrile. The limit of quantitation was 8 pmol/ml in blood and 24
pmol/g tissue in brain.
Open field behavior. The open field consisted of a 61  61  61 cm
Perspex box with dark walls and a white floor andwas dimly illuminated.
The open field was virtually divided into corridors along the walls (10 cm
wide; corners, 10 10 cm; and a center, 40 40 cm). Mice were put in
the middle of the open field and tracked by a camera connected to a
computer running on dedicated software (Ethovision, Noldus) for 10
min on 3 consecutive days. Vertical movements were registered, and
distance, corridor, corner, and center times were determined.
Morris water maze. TheMorris water maze used consisted of a 61-cm-
high plastic circular basin (diameter 1 m) approximately half filled with
water, with an invisible platform of 15  15 cm just under water in the
middle of one of four equal virtual segments (quadrants). Awhite curtain
surrounded the basin. Three asymmetrically applied intra-maze cues
were presented to the animals. The water was made turbid with white
dispersion paint. The mice were subjected to 1 training session per day
for 8 consecutive days. One training session consisted of 4 trials of 40 s
each. Time between trials was 10 s. The starting position in each trial was
quasi-random. If a mouse did not succeed in finding the platform, it
would be put onto it. The mice were tracked by a computer operating on
dedicated software (Ethovision; Noldus), which registered vertical
movements and calculated distance laid back, latency to the platform,
time in quadrant, and quadrant entries.
Gel electrophoresis and Western blotting. Forebrains were weighed and
homogenized by sonication in 10 volumes of Tris-buffered saline (TBS)
with Complete Inhibitor Cocktail (Roche Diagnostics). Homogenates
were run on 4–20% SDS-PAGE. C-terminal fragments were detected
with rabbit antiserumAPP-C8 raised against the C-terminal amino acids
of APP (Schrader-Fischer and Paganetti, 1996). ABCA1 was detected
with anti-ABCA1 antibody (1:200, Novus Biologicals, 100-1663), ApoE
with anti-ApoE (1:1000, Novus Biologicals, 100-2040), and -actin with
anti--actin (1:5000, Sigma, A2228).
Nondenaturing gradient gel electrophoresis. Samples of CSF weremixed
1:1 with native sample buffer and electrophoresed on 4–20% Tris-
Glycine gels (Invitrogen). Proteins with known hydrated diameters were
used as size standards (GE Healthcare). Proteins were transferred to a
nitrocellulose membrane and probed with anti-goat ApoE antibody
(Calbiochem, catalog #178479, 1:200) and secondary horse anti-goat IgG
linked HRP (Santa Cruz Biotechnology, Sc 2020, 1:2500), followed by
horse anti-goat IgG linked to HRP (Vector Laboratories, 1:1000). Bands
were visualized with enhanced chemiluminescence (Pierce) and imaged
with Syngene G:Box.
A determination by sandwich immunoassay on MSD Multi-Array
plate. Brain regions were weighed and homogenized by sonication in 10
volumes of TBS (20 mM Tris-HCl, pH 7.6, 137 mM sodium chloride, and
Complete Protease Inhibitor Cocktail; Roche Diagnostics). For determi-
nation of total A40 and A42, forebrain homogenates were extracted
for 15min at 4°C with 70% formic acid. The extracts were neutralized by
addition of 19 volumes of 1 M Tris-base and centrifuged for 15 min at
20,000  g. For determination of TBS-soluble A, forebrain homoge-
nates were centrifuged at 100,000 g for 15 min. For determination of
Triton X-100-soluble A, Triton X-100 was added to the forebrain ho-
mogenate (final concentration 1%) and samples were extracted on ice for
15min before centrifugation at 100,000 g. Samples weremixed every 5
min. Human (6E10) A40 or A42 ultra-sensitive kits were used (Meso
Scale Discovery). Triton X-100-soluble Awas diluted to a final concen-
tration of 1:100 with 3% Blocker A. Triton X-100 extracts were diluted
1:100. Signals were measured on a SECTOR Imager 6000 reader (Meso
Scale Discovery).
Determination of soluble APP and soluble APP by sandwich immu-
noassay onMSDmultiplex plate. Supernatants were diluted with 1% Tri-
ton X-100, TBS (final dilution 1:2000), loaded on an MS6000 soluble
APP (sAPP)/sAPPmultiplex plate (Meso Scale Discovery), and fur-
ther processed as described for A.
Detection of A aggregation. FAM-A1-42 (Peptide Specialty Labora-
tories) was solubilized as previously described (Teplow, 2006). In brief,
FAM-A1-42 was solubilized in 1,1,1–3,3,3-hexafluoroisopropanol, in-
cubated for 10min, and evaporated using a SpeedVac. FAM-A1-42 was
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resolubilized to 221 M in 10 mMNaOH, and aggregation was started by
dilution to 25 M using 50 mM Tris-HCl, pH 7. Samples were incubated
for 18 h at 37°C and flash-frozen in liquid nitrogen. Samples were stored
at 80°C afterward. Aggregation state was determined by sample sepa-
ration on 4–12% NuPAGE gel and Western blot using antibody 6E10
(Covance), followed by enhanced chemiluminescence detection (Milli-
pore) using HRP-conjugates (Jackson ImmunoResearch Laboratories).
Signals were analyzed using the Chemidoc XRS documentation system
(Bio-Rad).
Immunohistochemistry. Free-floating 40-m-thick serial sections were
cut on a vibratome (Leica). Sections obtained were stored in 0.1%NaN3,
PBS in a cold room. For immunohistochemistry, sections were treated
with 50% methanol for 15 min. Then, sections were washed three times
for 5 min in PBS and blocked in 3% BSA, 0.1% Triton X-100, PBS
(blocking buffer) for 30 min, followed by overnight incubation with the
primary antibody in blocking buffer. Next, sections were washed three
times in 0.1% Triton X-100, PBS, incubated with Alexa 488- or Alexa
594-conjugated secondary antibodies (1:500, Invitrogen) for 90min, and
washed three times with 0.1% Triton X-100, PBS for 5 min. Finally, the
sections were mounted on glasses in tap water and embedded inMowiol
solution with 0.1% 1,4-diazobicyclo[2.2.2]octan. The following primary
antibodies were used with respective concentrations: rabbit polyclonal
2964 against A (gift fromDr. JochenWalter, University of Bonn, Bonn,
Germany), rabbit polyclonal anti-ABCA1 (1:200, Novus Biologicals),
goat polyclonal anti-ApoE (1:200, M-20, sc-6384, Santa Cruz Biotech-
nology), rabbit polyclonal anti-ApoE (1:200, ab20874, Abcam), rabbit
polyclonal anti-GFAP (1:1000, Dako), rat monoclonal anti-mouse
CD11b (1:200, Serotec), and rabbit polyclonal anti-Iba1 (1:500, Wako,
Osaka, Japan). Fluorescence microscopy was performed using an Olym-
pus BX61 microscope, and images were processed in Cell-P (Olympus).
Primary microglial cell culture. Primary microglial cell cultures were
prepared as previously described in detail (Giulian and Baker, 1986).
Briefly, mixed glial cultures were prepared from newborn mice and cul-
tured in DMEM supplemented with 10% FCS and 100 U  ml1 penicil-
lin/streptomycin. Microglial cells were used after 10–14 d of primary
cultivation. They were harvested by shake-off, and replated and allowed
to attach to the substrate for 30 min. Attached cells were extensively
washed with culture medium and kept in culture for 1–2 d before being
used. For the experiments, wild-type, ApoE/ (Plump et al., 1992),
LXR/, LXR/, and LXR/// (Alberti et al., 2000) on a
C57BL/6 background were used.
Phagocytosis of FAM-labeled A1-42 by microglial cells. Microglial
phagocytosis of FAM-labeled A1-42 (FAM-A) (AnaSpec) was mea-
sured by plate-based assay as previously described (Floden and Combs,
2006). In brief, cells were plated at a density of 50,000 per well. Cells were
incubated with 500 nM A for up to 4 h, starting 1 h after plating. Finally,
the A-containing medium was removed and extracellular A was
quenchedwith 100l of 0.2% trypan blue in PBS, pH4.4, for 1min. After
aspiration, fluorescence was measured at 485 nm excitation/ 535 nm
emission using a SpectrafluorPlus reader (Tecan). To be able to normal-
ize for cell numbers, cells were incubated with 100 l of 50 g/ml
Hoechst 33342 in PBS for 30 min and fluorescence was measured at 360
nm excitation/465 nm emission. Additionally, the occurrence of micro-
glial Aphagocytosis was verified by confocal laser scanningmicroscopy.
Cells were fixed with 4% formaldehyde for 10 min and immunostained
using rat anti-mouse monoclonal antibody MCA711 for CD11b (Sero-
tec), and lysosomes were stained using LysoTracker Red (Invitrogen).
Confocal laser scanning microscopy was performed using an LSM 510
(Carl Zeiss). To validate the presence of aggregated Awithin microglia,
cells were incubated with aggregated A1-42 overnight and stained with
Thioflavin S. Fluorescencemicroscopywas performed using anOlympus
BX61.
Determination of plaque-associated microglia. Double-immunofluorescent
staining for CD11b and A was performed using the above-described
antibodies. Fields of plaques were randomly selected in the cortex. Im-
ages were made in Cell-P with automatic illumination. The area of
CD11b overlaying plaques was determined with the Colocalization
Finder plugin in NIH ImageJ 1.44 and corrected for total plaque area
determined with the subroutine Particle Analysis after background sub-
traction equal for all images and binarization. Only plaques with a diam-
eter smaller than 30 m were included in the analysis. Per-animal
coverage of 50–200 plaques by microglia was determined. Animal num-
ber per group was 7.
Statistical analysis. For statistical analysis, GraphPad Prism or SPSS
was used. ELISA,Western blot data, or image analysis data were analyzed
where appropriate by Student’s t test or two-way ANOVA followed by
Student’s t tests if indicated. Behavioral data on learning in the Morris
water maze were analyzed by three-way ANOVA, with transgene and
treatment as the independent between-subject variables and day as
within-subject variable, and distance or latency as the dependent vari-
ables. Integrated responses (area under the curve) were also analyzed for
the same between-subject and dependent variables. Probe trial data were
analyzed by three-way ANOVA with place (quadrant 1–4) as within-
subject variable, transgene and treatment as between-subject variables,
and time as dependent variable. Probe trial data were further analyzed
with repeated-measures ANOVAandTukey’s post hoc test. Data on open
field behavior were analyzed by three-way ANOVA with transgene
and treatment as between-subject dependent variables, day as within-
subject dependent variable, and time in corridor or center and dis-
tance laid back as dependent variables. Fluorescence measurements of
uptake of labeled A were analyzed by one-way ANOVA followed by
Tukey’s post hoc tests.
Results
Pharmacological treatment of APP23mice with the LXR
agonist TO901317
To test whether LXR activation by the pharmacological agonist
TO901317 affects the deposition of A, 13-month-old APP23
micewere treated for 7weeks with TO901317 (50mg/kg) by daily
oral gavage. To determine the penetration of TO901317 into the
brain, the compound concentrations in brain tissue and blood
were assessed at 4 h after the last dosing by LC/MS/MS. Treat-
ment with TO901317 for 7 weeks resulted in hind- and forebrain
concentrations that were substantially higher (approximately
threefold) than those found in the peripheral blood in both
APP23 mice and wild-type controls (Fig. 1A). Concentrations of
the compound in the brain reached values of 5 nmol/g fresh
weight, while those in the bloodwere2 nmol/ml. Assessment of
total body weight over the entire observation period did not re-
veal any differences in response to drug treatment (Fig. 1B),
which indicates that the drug was well tolerated. While serial
inspection of livers of TO901317-treated and untreated mice re-
vealed a tendency toward liver enlargement in response to treat-
ment, it seems important to note that this phenomenon did not
affect specific measures of animal well-being including ambula-
tion, grooming, skin condition, open field behavior, or weight
(see below). Notably, APP23 mice had a somewhat lower body
weight comparedwith controls (two-wayANOVA, p 0.001), in
accordance with their reported hypermetabolic condition
(Vloeberghs et al., 2008). The factor treatment did not affect
open field behavior (three-way ANOVAs, p values  0.05).
Open field behavior, assessed in the fifth week of treatment,
was not different between APP23 and wild-type mice, except
for a slightly higher activity of the transgenic mice on the first
day in the open field (interaction day transgene in the three-
way ANOVA and one-way ANOVA for the factor transgene on
day 1, p values 0.05) (Fig. 1C). The effect of day was highly
significant for all measures (three-way ANOVA, p values 
0.001), which means that the animals habituated to the open
field.
Inverse effects of TO901317 on A, ApoE, and ABCA1
Determination of forebrain A levels revealed a decrease by 40%
and 80%of both soluble and insolubleA1-40 andA1-42 levels,
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respectively, in response to TO901317
treatment (Fig. 2A,B). Analysis of APP
processing in TO901317- and vehicle-
treatedmice revealed a slight but significant
reduction of APP and soluble APP. Solu-
ble APP, C99, and C83 were not statisti-
cally different between groups (Fig. 2C).
Additionally, TO901317 treatment did not
alter the concentration of murine A in
wild-type mice (Fig. 2D). Immunohisto-
chemical analysis with an antibody directed
against fibrillar A confirmed the A-low-
ering effects of oral TO901317 treatment in
aged APP23 mice (Fig. 2E). Quantification
of Thioflavin S-stained A in brain sections
of TO901317-treated APP23 mice revealed
a strong reduction compared with non-
treated APP23 mice (Fig. 2F). Collectively,
these data suggest that the reduction of A
byTO901317wasnotmediatedbymodula-
tion of the APP processing pathway.
Treatment with TO901317 increased
concentrations of ABCA1 and ApoE in
APP23 and control mice (Fig. 3A–C). To
investigate which brain cells are most
likely to respond to TO901317, the distri-
bution of two proteins of which the genes
are targets for LXR, notably ABCA1 and
ApoE, was investigated by immunohisto-
chemistry.ABCA1wasdistributed through-
out the brain and could be shown to be
present in astrocytes (Fig. 3D). Its pres-
ence in astrocytes could still be observed
in the very fine ramifications where GFAP
staining is very faint or absent (data not
shown). ApoE was found in astrocytes as
well (Fig. 3E), as observed by others (Fu-
jita et al., 1999). ABCA1 and ApoE could
not be found to colocalize with CD11b-
positive microglia, regardless of their
morphological phenotype, which here at
the plaque site may reflect their re-
sponse to A (Fig. 3D,E), indicating
very low levels or even the absence of
these proteins in microglial cells in vivo.
Immunofluorescence for ABCA1 and
ApoE in astrocytes was not notably
stronger in the vicinity of plaques, demonstrating that expres-
sion of these proteins is not a marker for activated astroglia.
ABCA1 was present in astrocytes to the same extent in differ-
ent brain areas, whereas this distribution differs greatly for
GFAP. Treatment with TO901317 did not alter the cellular
localization of ABCA1 and ApoE (data not shown). Immuno-
staining using an anti-ABCA1 antibody was absent in brain
sections of ABCA1/ mice (Fig. 3D).
Spatial learning of TO901317-treated APP23 transgenics
Spatial learningwas assessed in theMorris watermaze in the sixth
to seventh week of treatment. A highly significant between-
subject effect for the factor strain was observed on the dependent
variables distance and latency ( p  0.001), indicating a spatial
memory deficit in the APP23 mice compared with controls (Fig.
4A). In addition, the effect of the within-subject factor day was
highly significant ( p values 0.01), indicating a learning effect.
An effect for the factor treatment was not observed on these
variables. In conclusion, APP23 mice exhibited a clear spatial
memory deficit in the Morris water maze test compared with
wild-type littermates.
Data were further analyzed with respect to overall perfor-
mance (average distance and latency for days 1–8), acquisition
(averages for day 1–4 of training), and consolidation (averages
for day 5–8 of training). The effect of the transgene was again
highly significant for performance overall, during acquisition
and consolidation (Fig. 4B,C). Post hoc analysis revealed aminor
worsening effect of the treatment during acquisition in the wild-
type animals and a minor improvement during consolidation in
the APP23 mice (Fig. 4B). Together, a beneficial effect was only
detectable during the consolidation but not during the acquisi-




Figure 1. TO901317 accumulates in the brain and does not affect bodyweight or basal behavior of mice in the open field upon
long-term treatment. A, Higher concentrations of TO901317 as determined with liquid chromatography tandem mass spectros-
copywere found in the hind- and forebrain comparedwith the peripheral blood 4 h after the last administration of TO9 01317 (50
mg/kg per day for 7 weeks). Number of hindbrains per group was 19–22, number of forebrains per group was 3. B, Body weight
ofwild-type (WT) andAPP23mice treatedwith either vehicle or TO901317 (TO)wasmonitored at the indicated time points during
the experimental period. Number of animals per group was 19–22. C, Distance laid back, corridor time, and center time of
indicated groups of mice in the open field were not affected by treatment with TO901317. Number of animals per group was 12.
Data represent means SEM.
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Three-way ANOVA of probe trial data revealed a significant
effect for the factor place (quadrant) ( p 0.01) and an interac-
tion between the factors place and transgene ( p  0.05) (Fig.
4D). Further statistical analysis revealed that these effects were
accounted for by a place preference of the wild-type mice (re-
peated measures one-way ANOVA and Tukey’s post hoc test, p
0.001) and the absence thereof in the APP23 mice (one-way
ANOVA, Tukey’s post hoc test, p 0.05). The probe trial revealed
that the wild-type mice used a spatial strategy, while the APP23
mice failed to do so. No treatment effects were observed on probe
trial performance.
Modulation of microglial A1-42 phagocytosis by the LXR
agonist TO901317
Phagocytosis of aged FAM-labeled A1-42 by microglia in vitro
was assayed as previously described by Floden and Combs
(2006), and controlled by laser confocal microscopy and immu-
noprecipitation ofA in lysates ofmicroglial cells. Aggregation of
Aupon agingwas verified byWestern blot analysis (Fig. 5A) and
detection of Thioflavin S-positive A in exposed microglia (Fig.
5A). Direct treatment of microglial cells for 2 h with the LXR
agonist TO901317 did not enhance A phagocytosis (Fig. 5A).
However, when A was presented in medium derived from as-
trocytes that were preexposed to increasing concentrations of the
LXR agonist (TO901317, 10 nM to 10 M) for 24 h, uptake by
microglia increased significantly in a dose-dependent manner,
suggesting that LXR agonist stimulated astrocytes to secrete a
product that positively regulates phagocytosis of A bymicroglia
(Fig. 5A). Importantly, generation of microglia conditioned me-
dia by preexposingmicroglial cells for up to 24 h toTO901317 did
not enhance A phagocytosis (data not shown).
Generation of primary astrocytic cultures from ApoE knock-
out mice was performed to test whether ApoE is critical for the
TO901317-mediated increase in phagocytosis of A by micro-
glia. Microglial cells that were exposed to conditioned media
from TO901317-treated wild-type astrocytes showed normal A
phagocytosis. In strong contrast, A phagocytosis was nearly ab-
sent when microglial cells were exposed to conditioned media
from TO901317-treated ApoE knock-out astrocytes, suggesting
that astrocyte-derived ApoE is indeed a critical factor (Fig. 5B).
Control experiments exposing ApoE intact or knock-out micro-
glia to TO901317 for an identical time period (24 h) showed that
the presence or absence of ApoE in microglia did not exert any
regulatory influence on subsequent A phagocytosis (data not
shown). A further set of experiments, using astrocyte cultures
generated fromLXR knock-out, LXR knock-out, and LXR/
knock-out mice, was performed to test whether the action of
TO901317 depends on the presence of LXR. A phagocytosis was
analyzed aftermicroglial cells were exposed to conditionedmedia
obtained from TO901317-treated wild-type, LXR knock-out,
LXR knock-out, or LXR/ knock-out astrocytes. Interest-
ingly, A phagocytosis was almost reduced to control levels when
microglial cells were exposed to media from both LXR knock-
out and LXR/ knock-out astrocytes, while media taken from






Figure 2. TO901317 reduces A burden in the APP23 transgenic mouse model of AD. A, B,
Concentrations of human A40 and A42 in formic acid extracts (A) or soluble fraction (B) in
APP23mice, as determined by sandwich ELISA,were strongly reduced in response to TO901317
(TO; 50 mg/kg per day for 7 weeks). 6E10 was used as a capture antibody and anti-A40 as
detection antibody. C, Sandwich immunoassay on Triton X-100 extracts or Western blot deter-
mination on brain homogenates showed a minor but significant reduction of APP and sAPP
uponTO901317 treatment. Capture antibodies in the sandwich immunoassaywereanti-sAPP
and anti-sAPP; reporter was anti-APP. ForWestern blot, detection of APP and the C-terminal
4
fragments 6E10was used.D, Endogenous A levels remained unaffected by drug treatment as
demonstrated by ECL immunoassay. E, Representativemicrographs of A immunohistochem-
istry with antibody 2964, showing the frontal cortex (Cx) or subiculum (Sb) of TO901317- and
vehicle-treatedAPP23mice. Asterisks indicate significant differences (unpaired Student’s t test,
*p 0.05, n 12). Data represent means SEM. F, Thioflavin S-positive area is reduced in
brain sections of APP23 mice treated with TO901317. Scale bars, 200m.WT, Wild type.
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collectively suggesting that the presence of
LXR is a key requirement for astrocyte-
mediated TO901317 action on microglial
phagocytosis (Fig. 5B). Together, these data
suggest that the stimulation of microglial
A phagocytosis by the LXR agonist
TO901317 greatly depended on both astro-
cytic ApoE and LXR.
To validate these in vitro findings, im-
munohistochemical costaining for micro-
glia andAwas performed in sections from
treated and untreated APP23mice. Because
of the reduced number of plaques, less acti-
vated microglia were found in TO901317-
treated APP23 mice generally. However,
remaining small plaques in TO901317-
treated APP23 mice demonstrated a closer
association with activated microglia com-
pared with those in controls (Fig. 5C). The
extent to which microglia were in close as-
sociation with small plaques, as defined by
yellow costaining of CD11b and A, was
quantifiedand turnedout tobe increasedby
tenfold (Fig. 5C). In additionwe studied the
effects of short-term treatment with
TO901317 in 13-month-old APP/PS1/
LXR/ andAPP/PS1/LXR/mice on
association of microglia with A in brain
and lipidationofApoE inCSF.Awasmore
covered by microglia in the presence of
LXR and TO901317, but this was not ob-
served in the absence of LXR (Fig. 6). Lipi-
dation of ApoE was investigated using
native gel electrophoresis. Migratory veloc-
ity of ApoE in the gel depends on lipidation
status. ApoE from CSF of APP/PS1/
LXR/ mice treated with TO901317
showed less lipidation than that of APP/PS1/
LXR/ mice treated with TO901317.
Note that the effect of TO901317 on ApoE
concentration did not depend on LXR.
Discussion
In human AD brain as well as in APP
transgenic mouse models, microglia re-
spond to aggregated and misfolded A
most visible in the vicinity of A plaques.
Experimental evidence, however, found
that they are inefficient in removing fibril-
lar A (Bolmont et al., 2008), suggesting
that either the deposition of A itself or
secondary metabolic or inflammatory
events lead to a progressive impairment of
microglial clearance function. Strategies
to overcome this microglial paralysis are
under intense investigation and include
vaccination against full-length or trun-
cated A peptides or stimulation of Toll-
like receptor signaling (Okura et al., 2008;
Scholtzova et al., 2009). Here it is demon-
strated that LXR activation is able to reset
microglial function, in particular, the ca-
pacity for A phagocytosis.
Figure 3. LXR activation positively regulates ApoE and ABCA1 expression in astrocytes. A, Densitometric quantification of
Western blot detection of ApoE in brain lysates fromAPP23 andwild-type (WT)mice treatedwith either vehicle or TO901317 (TO).
ApoE level was corrected for the level of the housekeeping protein actin. B, Densitometric analysis of Western blot detection of
ABCA1 inbrain lysates fromAPP23andwild-typemice treatedwith either vehicle or TO901317. ABCA1 levelwas corrected for actin
level.C, Representative images of ABCA1,ApoE, and-actinWesternblot detection inwild-typeorAPP23mice treatedwith either
vehicle or TO901317.D, E, Brain sections of vehicle-treatedmice showing neocortex (D) or hippocampus (E) were immunostained
for CD11b (microglial marker), GFAP (marker for astrocytic activation), and ApoE (D) or ABCA1 (E). The inset at the top of D shows
absence of immunostaining in ABCA1 knock-outmice,while the inset at the bottomdisplays the ABCA1 immunostaining at higher
magnification in the astrocytic arbors. Together, these immunostainings show that ApoE and ABCA1 expression is predominantly
located in astrocytes but not in microglia in the murine brain. Asterisks indicate significant differences (ANOVA, Student’s t test,
n 12, **p 0.01, ***p 0.001). Data represent means SEM. Scale bars, 100m, except inset, 25m.
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ApoE-dependent microglial phagocytosis of fibrillar A
contributes to LXR agonist-stimulated reduction in
amyloid pathology
The central finding of the present study is the ApoE-dependent
stimulation of microglial phagocytosis of fibrillar A by the LXR
agonist TO901317 in cell culture. Either the association of fibril-
lar A with ApoE or an effect of ApoE on microglia may be
responsible for the increased phagocytosis. Previously, it has been
observed that the LXRagonistGW3965 stimulates degradation of
soluble A in astroglial and microglial cultures dependent on
ApoE and its lipidation status (Jiang et al., 2008). These observa-
tions were proposed to explain the effect of long-term adminis-
tration of GW3965 on plaque-load in Tg2576 mice. However,
long-term treatment with TO901317 in 6-month-old APP23
mice did not have an effect on soluble A (Lefterov et al., 2007),
nor did it affect endogenous soluble A in wild-type mice (this
study).Moreover, the reduction of insoluble A by 80% found in
the present study seems to be too extensive to be caused by pre-
vention of A deposition alone, based on previously reported
age-dependent changes of insoluble A levels and disease pro-
gression in APP23 mice (Kuo et al., 2001). The hypothesis that
ApoE positively regulates the phagocytosis of aggregated A is
further supported by findings from Giunta et al. (2008), who
provided evidence that aged A phagocytosis is increased by re-
combinant ApoE3. More generally, but in line with our hypoth-
esis, Grainger et al. (2004) have shown that phagocytosis of
apoptotic thymocytes was reduced in ApoE-deficient macro-
phages, and this effect was corrected by addition of ApoE. To-
gether, these findings lend credit to a contributory role of
microglial phagocytosis of fibrillar A in vivo following LXR ac-
tivation. This hypothesis is further strengthened by the observa-
tion that activated microglial cells were closely associated with
remaining plaques in the TO901317-treatedAPP23mice. Next to
phagocytosis, however, other mechanisms, including release of
degrading proteases and peripheral clearance, may also be in-
volved in the reduction of A (Jiang et al., 2008).
In addition to increased phagocytosis, an altered interaction
between ApoE and A, influenced by the ApoE lipidation status,
might be partially responsible for the reduction of insolubleA in
TO901317-treated mice, similar to the proposed mechanism of
plaque reduction in PDAPP mice overexpressing ABCA1 (Wah-
rle et al., 2008). In keeping with this theory, PDAPP mice defi-
cient for ABCA1 reveal a plaque increase at advanced age
(Koldamova et al., 2005a; Wahrle et al., 2005). Long-term treat-
ment with TO901317 resulted in increased production of ApoE
and ABCA1 in aged, plaque-bearing APP23 mice, and was likely
to have led to increased amounts of lipidated ApoE. It is therefore
tempting to hypothesize that increased association of lipidated
ApoE with Amay have slowed down A aggregation and con-
tributed to the overall A reduction. However, a paradoxical
increase in soluble A reported for young ABCA1-
overexpressing PDAPPmice (Koldamova et al., 2005a;Wahrle et
al., 2008) and indicative of an altered interaction between soluble
ApoE and A, was not observed either in young APP23 mice
(Lefterov et al., 2007) or in control or aged APP23 mice (this
study) after long-term TO901317 treatment, together making
the alternative mechanism rather unlikely. However, a role for
toxic non-lipidated or poorly lipidated ApoE as a catalyst of A
aggregation cannot be excluded entirely on the basis of the re-
ported findings (Wahrle et al., 2005, 2008).
TO901317 resets microglia for phagocytosis of A in an
astrocyte- and LXR-dependent fashion
Interestingly, microglial A phagocytosis appeared to depend on
LXR and not LXR, since additional knock-out of LXR did
not reduce the effect of TO901317 any further than LXR knock-
out only. This is in accordance with abstract data from Riddell et
al. (2009) that show that only loss of LXR blocked the ability of
TO901317 to increase ApoE and reduce A levels. Other exam-
ples can be found in the literature that LXR and LXR are
nonredundant and canmediate differential effects when both are
Figure4. Spatialmemory learningofAPP23mice treatedwith TO901317.A, Timeneeded to
reach the hidden platform (latency in seconds) and distance traveled (in centimeters) in the
Morris maze by vehicle or TO901317 (TO)-treated APP23 (n 16) and wild-type (WT) mice
(n  16). B, C, Integrated distance traveled (area under the curve) (B) and time (C) were
determined for the whole observation period or divided in an acquisition (day 1–4) and a
consolidation (day 5–8) phase. Asterisks indicate significant differences (Student’s t test, *p
0.05). D, TO901317 treatment does not reinstate place preference in the Morris water maze in
APP23 mice. P, AL, O, and AR represent platform quadrant, and quadrant to the left, the right,
and opposite of P, respectively. Data represent means SEM. Groups consisted of 16 animals.
For detailed description of the statistics, see Results.
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present and stimulated by LXR agonists. For instance, it has been
shown that the ability of TO901317 to induce expression of
ABCA1 and ABCG1 is selectively impaired in LXR/ mac-
rophages (Bischoff et al., 2010). Nonredundant roles of LXR
and LXR are also in line with different studies on LXR and
LXR knock-out mice that have revealed that LXR has a
more important role in cholesterol homeostasis, whereas
LXR has functions in the immune system and neurons (Al-
Figure5. LXRagonistmodulationofmicroglial A1-42phagocytosis requires thepresenceof LXRandApoE inastrocytes.A, Uptakeof fibrillarAbymicroglial cells exposed tomediumderived
from either microglia (dir) or astrocytes (ind) treated with increasing concentrations of the LXR agonist TO901317. Western blot analysis demonstrated the time-dependent (from 0 to 18 h)
aggregation of A used for the described experiments. Immunocytochemical experiments, using fluorescence detection of an anti-phalloidin antibody to visualize cell boundaries (red), together
with FAM-A, were used to verify the intracellular localization of Awithinmicroglial cells. Thioflavin S staining detecting aggregated Awithinmicroglia was performed. Datawere analyzed by
ANOVA followed by Tukey’s post hoc test. Asterisks indicate significant differences from dir (n 5, *p 0.05, ***p 0.001).B, Analysis of microglial phagocytosis after coincubationwithmedia
derived from either ApoE/ or ApoE/ astrocytes exposed to TO901317 (10M) or vehicle (left), and analysis of microglial phagocytosis after coincubation with media derived from either
wild-type, LXR///, or LXR/// astrocytes exposed to TO901317 (10M) or vehicle (right). Data were analyzed by ANOVA followed by Tukey’s post hoc test. Number sign (#)
indicates difference from control ( p 0.001). Asterisks indicate differences from stimulated wild-type (**p 0.01, ***p 0.001). C, Microglia are more associated with plaques in APP23mice
after treatmentwith TO901317 (TO). Amyloid plaqueswere stainedwith rabbit polyclonal 2964 andmicrogliawithmonoclonal rat anti-CD11b. Datawere analyzedbyunpaired Student’s t test (n
7, **p 0.01). Data represent means SEM. Scale bars, 100m.
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berti et al., 2000, 2001; Wang et al., 2002; Steffensen et al.,
2004; Andersson et al., 2005; Kim et al., 2008). Moreover, even
though the affinity of TO901317 for LXR and LXRmay not
be different, the biological effects of TO901317 often indicate
a greater action through LXR (Fie´vet and Staels, 2009),
whereas, at least in hepatocytes and astrocytes, the abundance
of LXR is even greater than that of LXR (Tobin et al., 2000;
Abildayeva et al., 2006).
Colocalization of ApoE and ABCA1 supports central role of
astrocytes in cholesterol metabolism and ApoE lipidation in
the brain
ApoE is the primary cholesterol transporter in the brain and cho-
lesterol is loaded onto ApoE by ABCA1. However, the reported
distributions of ApoE and ABCA1 in the brain appear to mis-
match. ApoE has been found in astrocytes, whereas ABCA1 has
mainly been found in neurons in vivo (Koldamova et al., 2003). In
the present study, it was observed that both ApoE and ABCA1
colocalized in astrocytes,matching their site of synthesis and sug-
gesting that the levels of the respective proteins may be consider-
ably higher in astrocytes compared with neurons and microglia.
Therefore, the lattermay contain someABCA1 andApoE, but are
unlikely to provide the bulk of lipidated ApoE. Microglial ApoE
synthesis has been observed in vivo under certain conditions,
such as kainic acid treatment (Xu et al., 2006), but neither the
presence of A nor TO901317 treatment appears to stimulate
ApoE production by microglia in vivo (this study).
Behavioral effects of TO901317 in AD models
The present study confirmed the spatial learning impairment
generally observed in APP23 mice (Van Dam et al., 2003, 2008;
Buxbaum et al., 2008). Although a major effect of the compound
on plaque pathology was observed, the effect on behavior was
minor. The treatment was started at a stage during which APP23
mice are known to already have a considerable plaque-load and
show A plaque-associated microglia. Possibly, the impairment
in neuronal function caused byA cannot be fully reversed at this
stage. A is toxic to synapses (Koffie et al., 2009), and synapto-
toxicity may have caused synaptic dysfunction or even loss in
agedAPP23mice that cannot be easily restored. Future therapeu-
tic approaches should aim, therefore, at prevention or combine
reduction of pathology with restoration of neuronal circuitry.
Different studies have been performed on the effect of long-
term treatment with LXR agonists on amyloid- and/or behavior
in mice expressing mutant APP or APP and PS1. Jiang et al.
(2008) found a reduction in plaque-load in 16-month-old
Tg2576 mice, but tested behavior in 5-month-old Tg2576 mice.
In contrast, Vanmierlo et al. (2009) did not find a reduction in
plaque-load, but found a behavioral improvement in 23-month-
old APPSLxPS1mut mice. In the present study, a reduction in
plaque-load was observed in 13-month-old APP23 mice, but
only a minor behavioral improvement. The differences between
these studies are likely to be found in differences in animal mod-
els, ages, dosage of compound, type of compound, and routes and
duration of administration used. For example, in the study by
Lefterov et al. (2007) and in the present study, oral gavage of 50
mg/kg TO901317 per day was used, whereas Vanmierlo et al.
(2009) administered the compound in the food at a lower dose
(30 mg/kg per day). Vanmierlo et al. (2009) determined the op-
timal dose by short-term treatment regimens. However, Lefterov
et al. (2007) observed that drug effects wear off with time of
treatment. Positive effects were observed with relatively simple
cognitive tests, such as fear conditioning in preplaque Tg2576
mice and object recognition in plaque-bearing APPSLxPS1mut
mice (Riddell et al., 2007; Jiang et al., 2008; Vanmierlo et al.,
2009). In the present study, a minor drug effect was observed in
the Morris water maze task, probably because this task requires
more complex cognitive modalities and therefore may be more
demanding.
Conclusion
In conclusion, long-termTO901317 treatment in plaque-bearing
APP23 mice is able to ameliorate amyloid pathology, but only
mildly improves spatial memory performance. TO901317 may
affect the clearance of insoluble A, best explained by a stimula-
tion ofmicroglial phagocytosis of fibrillar A. This effect appears
to be selectively mediated through LXR. To fully exploit the
Figure 6. LXRmediates ApoE lipidation and increased microglial A plaque associa-
tion. A, Native Western blot detection of ApoE in CSF derived from TO901317 (TO)- and
vehicle (Veh)-treated APP/PS1/LXR/ and APP/PS1/LXR/mice. B, Quantitative
analysis of microglial plaque association from TO901317 and vehicle-treated APP/PS1/
LXR/ and APP/PS1/LXR/ mice. C, Representative images showing CD11b-
positive microglia associated with A-positive plaques in neocortex of TO901317-treated
APP/PS1/LXR/ and APP/PS1/LXR/ mice. Data represent means SEM. Data
were analyzed by two-way ANOVA, followed by Student’s t test (n 4, *p 0.05, #p
0.01). Scale bars, 100m.
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potential of LXR agonists in AD models, treatment probably
should be initiated at the time A starts to deposit and be sus-
tained into old age.
References
Abildayeva K, Jansen PJ, Hirsch-ReinshagenV, Bloks VW, Bakker AH, Ramaek-
ers FC, de Vente J, Groen AK,Wellington CL, Kuipers F, Mulder M (2006)
24(S)-Hydroxycholesterol participates in a liver X receptor-controlled path-
way in astrocytes that regulates apolipoproteinE-mediated cholesterol efflux.
J Biol Chem 281:12799–12808.
Alberti S, Steffensen KR, Gustafsson JA (2000) Structural characterisation
of the mouse nuclear oxysterol receptor genes LXRalpha and LXRbeta.
Gene 243:93–103.
Alberti S, Schuster G, Parini P, FeltkampD,DiczfalusyU, RudlingM,Angelin
B, Bjo¨rkhem I, Pettersson S, Gustafsson JA (2001) Hepatic cholesterol
metabolism and resistance to dietary cholesterol in LXRbeta-deficient
mice. J Clin Invest 107:565–573.
Andersson S, Gustafsson N, Warner M, Gustafsson JA (2005) Inactivation
of liver X receptor beta leads to adult-onsetmotor neuron degeneration in
male mice. Proc Natl Acad Sci U S A 102:3857–3862.
BaranowskiM (2008) Biological role of liver X receptors. J Physiol Pharma-
col 59:31–55.
Beaven SW, Tontonoz P (2006) Nuclear receptors in lipid metabolism: tar-
geting the heart of dyslipidemia. Annu Rev Med 57:313–329.
Bischoff ED, Daige CL, Petrowski M, Dedman H, Pattison J, Juliano J, Li AC,
Schulman IG (2010) Non-redundant roles for LXRalpha and LXRbeta
in atherosclerosis susceptibility in low density lipoprotein receptor
knockout mice. J Lipid Res 51:900–906.
Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, Kohsaka S,
Jucker M, Calhoun ME (2008) Dynamics of the microglial/amyloid in-
teraction indicate a role in plaque maintenance. J Neurosci 28:
4283–4292.
Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P, Golde T, Masliah E,
Roberts AR, Bartfai T (2008) Transthyretin protects Alzheimer’s mice
from the behavioral and biochemical effects of A beta toxicity. Proc Natl
Acad Sci U S A 105:2681–2686.
DeMattos RB, Bales KR, Parsadanian M, O’Dell MA, Foss EM, Paul SM,
Holtzman DM (2002) Plaque-associated disruption of CSF and plasma
amyloid-beta (A beta) equilibrium in a mouse model of Alzheimer’s dis-
ease. J Neurochem 81:229–236.
Fie´vet C, Staels B (2009) Liver X receptor modulators: effects on lipid me-
tabolism and potential use in the treatment of atherosclerosis. Biochem
Pharmacol 77:1316–1327.
Floden AM, Combs CK (2006) beta-amyloid stimulates murine postnatal
and adult microglia cultures in a unique manner. J Neurosci
26:4644–4648.
Fujita SC, Sakura K, Tsuchiya R, Hamanaka H (1999) Apolipoprotein E is
found in astrocytes but not in microglia in the normal mouse brain.
Neurosci Res 35:123–133.
Giulian D, Baker TJ (1986) Characterization of ameboid microglia isolated
from developing mammalian brain. J Neurosci 6:2163–2178.
Giunta B, Zhou Y, Hou H, Rrapo E, Fernandez F, Tan J (2008) HIV-1 TAT
inhibits microglial phagocytosis of Abeta peptide. Int J Clin Exp Pathol
1:260–275.
Grainger DJ, Reckless J, McKilligin E (2004) Apolipoprotein E modulates
clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic
proinflammatory state in apolipoprotein E-deficient mice. J Immunol
173:6366–6375.
Heneka MT, O’Banion MK (2007) Inflammatory processes in Alzheimer’s
disease. J Neuroimmunol 184:69–91.
Jankowsky JL, Slunt HH, Gonzales V, Jenkins NA, Copeland NG, Borchelt
DR (2004) APP processing and amyloid deposition in mice haplo-
insufficient for presenilin 1. Neurobiol Aging 25:885–892.
Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K,
Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA,
Riddell D, Holtzman DM, Tontonoz P, Landreth GE (2008) ApoE pro-
motes the proteolytic degradation of A beta. Neuron 58:681–693.
Kim HJ, Fan X, Gabbi C, Yakimchuk K, Parini P, Warner M, Gustafsson JA
(2008) Liver X receptor beta (LXRbeta): a link between beta-sitosterol
and amyotrophic lateral sclerosis-Parkinson’s dementia. Proc Natl Acad
Sci U S A 105:2094–2099.
KimWS, Rahmanto AS, Kamili A, Rye KA, Guillemin GJ, Gelissen IC, Jessup
W,Hill AF,Garner B (2007) Role of ABCG1 andABCA1 in regulation of
neuronal cholesterol efflux to apolipoprotein E discs and suppression of
amyloid-beta peptide generation. J Biol Chem 282:2851–2861.
Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML,
Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, Hyman BT,
Spires-Jones TL (2009) Oligomeric amyloid beta associates with post-
synaptic densities and correlates with excitatory synapse loss near senile
plaques. Proc Natl Acad Sci U S A 106:4012–4017.
Koldamova RP, Lefterov IM, Ikonomovic MD, Skoko J, Lefterov PI, Isanski
BA, DeKosky ST, Lazo JS (2003) 22R-Hydroxycholesterol and 9-cis-
retinoic acid induce ATP-binding cassette transporter A1 expression and
cholesterol efflux in brain cells and decrease amyloid beta secretion. J Biol
Chem 278:13244–13256.
Koldamova R, Staufenbiel M, Lefterov I (2005a) Lack of ABCA1 consider-
ably decreases brain ApoE level and increases amyloid deposition in
APP23 mice. J Biol Chem 280:43224–43235.
Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC,
Walter M, Roth MG, Lazo JS (2005b) The liver X receptor ligand
T0901317 decreases amyloid beta production in vitro and in a mouse
model of Alzheimer’s disease. J Biol Chem 280:4079–4088.
Kuo YM, Beach TG, Sue LI, Scott S, Layne KJ, Kokjohn TA, Kalback WM,
Luehrs DC, Vishnivetskaya TA, Abramowski D, Sturchler-Pierrat C,
Staufenbiel M, Weller RO, Roher AE (2001) The evolution of A beta
peptide burden in the APP23 transgenic mice: implications for A beta
deposition in Alzheimer disease. Mol Med 7:609–618.
Lefterov I, Bookout A,Wang Z, Staufenbiel M,Mangelsdorf D, Koldamova R
(2007) Expression profiling in APP23 mouse brain: inhibition of A beta
amyloidosis and inflammation in response to LXR agonist treatment.Mol
Neurodegener 2:20.
Mulder M, Terwel D (1998) Possible link between lipid metabolism and
cerebral amyloid angiopathy in Alzheimer’s disease: a role for high-
density lipoproteins? Haemostasis 28:174–194.
Okura Y, Kohyama K, Park IK, Matsumoto Y (2008) Nonviral DNA vacci-
nation augments microglial phagocytosis of beta-amyloid deposits as a
major clearance pathway in an Alzheimer disease mouse model. J Neuro-
pathol Exp Neurol 67:1063–1071.
Plump AS, Smith JD, Hayek T, Aalto-Seta¨la¨ K, Walsh A, Verstuyft JG, Rubin
EM, Breslow JL (1992) Severe hypercholesterolemia and atherosclerosis
in apolipoprotein E-deficient mice created by homologous recombina-
tion in ES cells. Cell 71:343–353.
Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, Ring
RH, Kirksey Y, Aschmies S, Xu J, Kubek K, Hirst WD, Gonzales C, Chen
Y,Murphy E, Leonard S, VasylyevD, Oganesian A,Martone RL, Pangalos
MN, et al (2007) The LXR agonist TO901317 selectively lowers hip-
pocampal Abeta42 and improves memory in the Tg2576mouse model of
Alzheimer’s disease. Mol Cell Neurosci 34:621–628.
Roses AD (2006) On the discovery of the genetic association of apolipopro-
tein E genotypes and common late-onset Alzheimer disease. J Alzheimers
Dis 9:361–366.
Scholtzova H, Kascsak RJ, Bates KA, Boutajangout A, Kerr DJ, Meeker HC,
Mehta PD, Spinner DS, Wisniewski T (2009) Induction of Toll-like re-
ceptor 9 signaling as a method for ameliorating Alzheimer’s disease-
related pathology. J Neurosci 29:1846–1854.
Schrader-Fischer G, Paganetti PA (1996) Effect of alkalizing agents on the
processing of the beta-amyloid precursor protein. Brain Res 716:91–100.
Steffensen KR, Neo SY, Stulnig TM, Vega VB, Rahman SS, Schuster GU,
Gustafsson JA, Liu ET (2004) Genome-wide expression profiling; a
panel of mouse tissues discloses novel biological functions of liver X re-
ceptors in adrenals. J Mol Endocrinol 33:609–622.
Sturchler-Pierrat C, AbramowskiD,DukeM,WiederholdKH,Mistl C, Roth-
acher S, Ledermann B, Bu¨rki K, Frey P, Paganetti PA,Waridel C, Calhoun
ME, JuckerM, Probst A, StaufenbielM, Sommer B (1997) Two amyloid
precursor protein transgenic mouse models with Alzheimer disease-like
pathology. Proc Natl Acad Sci U S A 94:13287–13292.
Teplow DB (2006) Preparation of amyloid beta-protein for structural and
functional studies. Methods Enzymol 413:20–33.
Tobin KA, Steineger HH, Alberti S, Spydevold O, Auwerx J, Gustafsson JA,
Nebb HI (2000) Cross-talk between fatty acid and cholesterol metabo-
lism mediated by liver X receptor-alpha. Mol Endocrinol 14:741–752.
Van Dam D, D’Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De
Deyn PP (2003) Age-dependent cognitive decline in the APP23 model
precedes amyloid deposition. Eur J Neurosci 17:388–396.
7058 • J. Neurosci., May 11, 2011 • 31(19):7049–7059 Terwel et al. • Liver X Receptor- in AD
Van Dam D, Coen K, De Deyn PP (2008) Cognitive evaluation of disease-
modifying efficacy of donepezil in the APP23 mouse model for Alzhei-
mer’s disease. Psychopharmacology 197:37–43.
VanmierloT, RuttenK,Dederen J, BloksVW, vanVark-vanderZee LC,Kuipers F,
KiliaanA, BloklandA, Sijbrands EJ, SteinbuschH, Prickaerts J, LutjohannD,
Mulder M (2009) Liver X receptor activation restores memory in aged AD
mice without reducing amyloid. Neurobiol Aging. Advance online publica-
tion. Retrieved Aug. 11, 2009. doi:10.1016/j.neurobiolaging.2009.07.005.
Vloeberghs E, Van Dam D, Franck F, Serroyen J, Geert M, Staufenbiel M, De
Deyn PP (2008) Altered ingestive behavior, weight changes, and intact ol-
factory sense in anAPPoverexpressionmodel. BehavNeurosci 122:491–497.
Wahrle SE, Jiang H, ParsadanianM, Hartman RE, Bales KR, Paul SM, Holtz-
man DM (2005) Deletion of Abca1 increases Abeta deposition in the
PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem
280:43236–43242.
Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-
Reinshagen V,Wellington CL, Bales KR, Paul SM,HoltzmanDM (2008)
Overexpression of ABCA1 reduces amyloid deposition in the PDAPP
mouse model of Alzheimer disease. J Clin Invest 118:671–682.
Wang L, Schuster GU, Hultenby K, Zhang Q, Andersson S, Gustafsson JA
(2002) Liver X receptors in the central nervous system: from lipid ho-
meostasis to neuronal degeneration. Proc Natl Acad Sci U S A 99:
13878–13883.
Whitney KD,WatsonMA, Goodwin B, Galardi CM,Maglich JM,Wilson JG,
Willson TM, Collins JL, Kliewer SA (2001) Liver X receptor (LXR) reg-
ulation of the LMR alpha gene in human macrophages. J Biol Chem
276:43509–43515.
Whitney KD,WatsonMA, Collins JL, BensonWG, Stone TM, NumerickMJ,
Tippin TK, Wilson JG, Winegar DA, Kliewer SA (2002) Regulation of
cholesterol homeostasis by the liver X receptors in the central nervous
system. Mol Endocrinol 16:1378–1385.
Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y (2006)
Profile and regulation of apolipoprotein E (ApoE) expression in the CNS
inmicewith targeting of green fluorescent protein gene to theApoE locus.
J Neurosci 26:4985–4994.
Zelcer N, Tontonoz P (2006) Liver X receptors as integrators of metabolic
and inflammatory signaling. J Clin Invest 116:607–614.
Terwel et al. • Liver X Receptor- in AD J. Neurosci., May 11, 2011 • 31(19):7049–7059 • 7059
